These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 34452051)

  • 1. Adverse Effects on Work and Daily Life Interference among Healthcare Workers after the First and Second ChAdOx1 and BNT162b2 COVID-19 Vaccine Doses.
    Park C; Sakong J; Jo S; Kim M; Baek K
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum Antibody Response Comparison and Adverse Reaction Analysis in Healthcare Workers Vaccinated with the BNT162b2 or ChAdOx1 COVID-19 Vaccine.
    Lim SH; Choi SH; Kim B; Kim JY; Ji YS; Kim SH; Kim CK; Kim T; Choo EJ; Moon JE; Yun J; Park SK
    Vaccines (Basel); 2021 Nov; 9(12):. PubMed ID: 34960125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse Reactions Following the First Dose of ChAdOx1 nCoV-19 Vaccine and BNT162b2 Vaccine for Healthcare Workers in South Korea.
    Bae S; Lee YW; Lim SY; Lee JH; Lim JS; Lee S; Park S; Kim SK; Lim YJ; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH
    J Korean Med Sci; 2021 May; 36(17):e115. PubMed ID: 33942579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Events in Healthcare Workers after the First Dose of ChAdOx1 nCoV-19 or BNT162b2 mRNA COVID-19 Vaccination: a Single Center Experience.
    Kim SH; Wi YM; Yun SY; Ryu JS; Shin JM; Lee EH; Seo KH; Lee SH; Peck KR
    J Korean Med Sci; 2021 Apr; 36(14):e107. PubMed ID: 33847085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Antibody and T Cell Responses Induced by Single Doses of ChAdOx1 nCoV-19 and BNT162b2 Vaccines.
    Kim JY; Bae S; Park S; Kwon JS; Lim SY; Park JY; Cha HH; Seo MH; Lee HJ; Lee N; Heo J; Shum D; Jee Y; Kim SH
    Immune Netw; 2021 Aug; 21(4):e29. PubMed ID: 34522442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac.
    Wanchaijiraboon P; Sainamthip P; Teeyapun N; Luangdilok S; Poovorawan Y; Wanlapakorn N; Tanasanvimon S; Sriuranpong V; Susiriwatananont T; Zungsontiporn N; Pakvisal N
    Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851234
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An Immunogenicity Report for the Comparison between Heterologous and Homologous Prime-Boost Schedules with ChAdOx1-S and BNT162b2 Vaccines.
    Vallée A; Vasse M; Mazaux L; Bonan B; Amiel C; Zia-Chahabi S; Chan-Hew-Wai A; Farfour E; Camps E; Touche P; Barret F; Parquin F; Zucman D; Fourn E
    J Clin Med; 2021 Aug; 10(17):. PubMed ID: 34501264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impacts of Side Effects to BNT162b2 and the First Dose of ChAdOx1 Anti-SARS-CoV-2 Vaccination on Work Productivity, the Need for Medical Attention, and Vaccine Acceptance: A Multicenter Survey on Healthcare Workers in Referral Teaching Hospitals in the Republic of Korea.
    Kim T; Park SY; Yu S; Park JW; Lee E; Jeon MH; Kim TH; Choo EJ
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34198562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
    Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
    Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early Adverse Events between mRNA and Adenovirus-Vectored COVID-19 Vaccines in Healthcare Workers.
    Wi YM; Kim SH; Peck KR
    Vaccines (Basel); 2021 Aug; 9(8):. PubMed ID: 34452055
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adverse Events Following Immunization Associated with the First and Second Doses of the ChAdOx1 nCoV-19 Vaccine among Healthcare Workers in Korea.
    Jeon M; Kim J; Oh CE; Lee JY
    Vaccines (Basel); 2021 Sep; 9(10):. PubMed ID: 34696204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between Immunoglobulin G Levels and Adverse Effects Following Vaccination with the BNT162b2 Vaccine among Japanese Healthcare Workers.
    Otani J; Ohta R; Sano C
    Vaccines (Basel); 2021 Oct; 9(10):. PubMed ID: 34696257
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reactogenicity after the first and second doses of BNT162b2 mRNA coronavirus disease vaccine: a single-center study.
    Kang YM; Lim J; Choe KW; Lee KD; Jo DH; Kim MJ; Kim JM; Kim KN
    Clin Exp Vaccine Res; 2021 Sep; 10(3):282-289. PubMed ID: 34703812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers.
    Kadali RAK; Janagama R; Peruru S; Malayala SV
    Int J Infect Dis; 2021 May; 106():376-381. PubMed ID: 33866000
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse Reactions of the Second Dose of the BNT162b2 mRNA COVID-19 Vaccine in Healthcare Workers in Korea.
    Lee YW; Lim SY; Lee JH; Lim JS; Kim M; Kwon S; Joo J; Kwak SH; Kim EO; Jung J; Kwon HS; Kim TB; Kim SH; Bae S
    J Korean Med Sci; 2021 May; 36(21):e153. PubMed ID: 34060261
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
    Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
    JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutralizing Anti-SARS-CoV-2 Antibody Titer and Reported Adverse Effects, in a Sample of Italian Nursing Home Personnel after Two Doses of the BNT162b2 Vaccine Administered Four Weeks Apart.
    Modenese A; Paduano S; Bargellini A; Bellucci R; Marchetti S; Bruno F; Grazioli P; Vivoli R; Gobba F
    Vaccines (Basel); 2021 Jun; 9(6):. PubMed ID: 34203652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Arterial events, venous thromboembolism, thrombocytopenia, and bleeding after vaccination with Oxford-AstraZeneca ChAdOx1-S in Denmark and Norway: population based cohort study.
    Pottegård A; Lund LC; Karlstad Ø; Dahl J; Andersen M; Hallas J; Lidegaard Ø; Tapia G; Gulseth HL; Ruiz PL; Watle SV; Mikkelsen AP; Pedersen L; Sørensen HT; Thomsen RW; Hviid A
    BMJ; 2021 May; 373():n1114. PubMed ID: 33952445
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic Adverse Events and Use of Antipyretics Predict the Neutralizing Antibody Positivity Early after the First Dose of ChAdOx1 Coronavirus Disease Vaccine.
    Park JY; Choi SH; Chung JW; Hwang MH; Kim MC
    J Clin Med; 2021 Jun; 10(13):. PubMed ID: 34199053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of severe adverse events among health professionals after receiving the first dose of the ChAdOx1 nCoV-19 coronavirus vaccine (Covishield) in Togo, March 2021.
    Konu YR; Gbeasor-Komlanvi FA; Yerima M; Sadio AJ; Tchankoni MK; Zida-Compaore WIC; Nayo-Apetsianyi J; Afanvi KA; Agoro S; Salou M; Landoh DE; Nyansa AB; Boko E; Mijiyawa M; Ekouevi DK
    Arch Public Health; 2021 Nov; 79(1):207. PubMed ID: 34819146
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.